A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Public ClinicalTrials.gov record NCT04564027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
Study identification
- NCT ID
- NCT04564027
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2020 (Actual)
- Primary completion
- Feb 18, 2025 (Actual)
- Completion
- Feb 18, 2025 (Actual)
- Last update posted
- Aug 29, 2025
2020 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Duarte | California | 91010 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Las Vegas | Nevada | 89119 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Ephrata | Pennsylvania | 17522 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04564027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04564027 live on ClinicalTrials.gov.